Phase 2 Clinical Trials to Evaluate the Safety and Efficacy of IMSA101 STING Agonist in Combination with Radiotherapy and Checkpoint Inhibitors in Oligometastatic (OMD) and Oligoprogressive (OPD) Solid Tumors. 2024 ASCO Annual Meeting.
